KPSGill Intelligence

From the September 25, 2026 edition

Earlier this month · 21–25 September

Editorial illustration: Outreach workers from a mobile behavioral-health team talk with people outside a community centre at sunset — Editorial illustration — not a photograph of the reported event.

U.S. health · 25 Sept · Awards made

Nearly $250 million moves into behavioral health and addiction services

$247.9 million in SAMHSA awards: $69.4M for medication treatment of opioid use disorder, $34.6M for first-responder overdose reversal, $54.9M for school mental health, $41.8M for child-trauma centres, plus recovery and workforce programmes.

Primary HHS announcement, 25 Sept

Editorial illustration: a clinician explains a once-weekly insulin pen to a patient in a Central Valley clinic — Editorial illustration — not a photograph of the reported event.

Clinical · FDA · 24 Sept

Once-weekly insulin reaches U.S. practice

FDA approves Onswik (insulin efsitora alfa-gobe) for adults with type 2 diabetes, with a warning against use in type 1 diabetes because of increased severe-hypoglycemia risk.

Primary FDA approval notice KPSGill Understanding type 2 diabetes

Editorial illustration: Delegates seated around a circular conference table beneath the United Nations emblem, with outbreak maps on screens — Editorial illustration — not a photograph of the reported event.

Global · United Nations · High-level meeting · 25 Sept

Pandemic preparedness returns to the UN’s top table

Governments meet in New York over surveillance, financing, health-system resilience and equitable access. No outcome is reported until the UN posts it.

Primary UN meeting page · live event · webcast Context WHO at UNGA 2026

Editorial illustration: An oncologist points to a kidney tumour on a CT scan while talking with a patient — Editorial illustration — not a photograph of the reported event.

Clinicians · FDA · 24 Sept · PFS 14.6 vs 10.6 months

Kidney-cancer combination improves progression-free survival

Belzutifan plus lenvatinib after PD-1/PD-L1 therapy: median progression-free survival 14.6 vs 10.6 months; the final overall-survival difference was not statistically significant.

Primary FDA approval notice

VetoedAB 539 · 20 September 2026

California · Vetoed · 20 Sept

AB 539 will not become California’s prior-authorization duration law

The Governor vetoed the measure on 20 September; it is recorded as vetoed on the Governor’s desk.

Primary veto message (PDF) Context Governor’s 20 Sept update KPSGill AB 539 dossier · Governor’s desk

Record corrected

AB 539 (prior authorization: duration of approval) was vetoed on 20 September 2026; an earlier front-page status for this bill is superseded. Primary veto message (PDF) Context Governor’s legislative update, 20 Sept